Retinal Vein Occlusion Market 2024 Report By Key Companies, Regional Analysis And Forecast 2033

The new report published by The Business Research Company, titled Retinal Vein Occlusion Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the retinal vein occlusion market size has grown rapidly in recent years. It will grow from $13.79 billion in 2023 to $15.43 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The retinal vein occlusion market size is expected to see rapid growth in the next few years. It will grow to $23.08 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13058&type=smp

Rising Prevalence Of Eye Disorders Fuels Growth In The Ocular Drug Delivery Market
An increase in the prevalence of eye disorders is expected to propel the growth of the ocular drug delivery market going forward. Eye disorders refer to a wide range of conditions that affect the eyes, vision, or the structures surrounding the eyes. The increased incidence of renal vein occlusion drives growth in the renal vein occlusion market, fostering demand for innovative diagnostics and treatments to address this condition. For instance, in March 2023, according to the World Health Organization, a Switzerland-based United Nations agency, globally, 2.2 billion people will have a near- or far-sighted impairment, according to estimates, cataracts (94 million) and uncorrected refractive problems (88.4 million) are the main causes of visual loss or impaired vision. In addition, glaucoma (7.7 million cases), corneal opacities (4.2 million cases), diabetic retinopathy (3.9 million cases) and trachoma (2 million cases) are the other common causes of vision loss. Therefore, the increasing prevalence of eye disorders will drive the retinal vein occlusion market.

Pioneering Innovations In The Retinal Vein Occlusion Market To Gain Competitive Advantage
Companies operating in the retinal vein occlusion market are adopting novel approaches to enhance patient care and treatment outcomes and sustain their position in the market. Advancements in drug development can increase treatment options for RVO, providing more targeted and effective treatment. For instance, in April 2023, Iridex Corporation, a US-based ophthalmic medical technology company, launched the next-generation Iridex PASCAL. The brand-new platform offers a cutting-edge technology package that combines rapid and accurate pattern scanning abilities, endpoint management technology, a pattern scanning laser trabeculoplasty and micropulse technology in a more compact, ergonomically designed integrated laser platform to provide individualized care to patients with retinal disease.

The retinal vein occlusion market covered in this report is segmented -

1) By Type: Branch Retinal Artery Occlusion; Central Retinal Vein Occlusion
2) By Condition: Non-Ischemic; Ischemic
3) By Diagnosis: Optical Coherence Tomography; Fundoscopic Examination; Fluorescein Angiography
4) By Treatment: Antivascular Endothelial Growth Factor; Corticosteroid Drugs; Laser Retinal Photocoagulation
5) By End User: Hospitals And Clinics; Research And Academics Centers; Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13058&type=discount

Major players in the retinal vein occlusion market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Amgen Inc., Allergan PLC, Regeneron Pharmaceuticals Inc., Biogen Idec Inc., Vertex Pharmaceuticals Inc., Bausch Health Companies Inc., Carl Zeiss AG, Santen Pharmaceutical Co. Ltd., Lumenis Ltd., Coherus Biosciences Inc., Genentech Inc., Topcon Corporation, Nidek Co. Ltd., IRIDEX Corporation, Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Ellex Medical Lasers Ltd., Adverum Biotechnologies Inc., Avik Pharmaceutical Limited (Avik), Outlook Therapeutics Inc., Annexin Pharmaceuticals AB, Ingenia Therapeutics Inc.

Contents of the report:
1. Executive Summary
2. Retinal Vein Occlusion Market Report Structure
3. Retinal Vein Occlusion Market Trends And Strategies
4. Retinal Vein Occlusion Market - Macro Economic Scenario
5. Retinal Vein Occlusion Market Size And Growth
…..
27. Retinal Vein Occlusion Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.